3 Outperforming IPO Stocks Flying Under The Radar

BEAM gained 87.1% within two days of its market debut. However, in the wake of rising coronavirus cases and a countrywide lockdown, the stock plummeted 59.1% to hit its 52-week low in March. BEAM has since gained more than 605%, hitting its all-time high of $91.94 yesterday.

The company is currently developing a pipeline of drugs for sickle cell disease and glycogen storage disease. In October, BEAM raised an additional $135 million through a follow-on offering of 12.50 million shares at $23.50 per share.

BEAM’s EPS is expected to rise 85.2% in the current quarter, 78.6% in the current year, and 12.6% next year.

How does BEAM stack up for POWR Ratings?

A for Trade Grade

A for Buy & Hold Grade

A for Peer Grade

B for Industry Rank

A for Overall POWR Rating.

It is currently ranked #19of 403 stocks in the Biotech industry.

I-Mab (IMAB - Get Rating)

IMAB is a Chinese biopharmaceutical company focused on developing novel or highly differentiated biologics for autoimmune diseases and cancer treatments. IMAB began trading on NASDAQ on January 17. It raised $119.26 billion through its IPO of 7.41 million American Depository Shares.

Yesterday, IMAB was added to the NASDAQ Biotechnology Index, which tracks the largest biopharma companies listed on the stock exchange, yesterday.

In September, the company entered a global partnership with AbbVie to develop differentiated Immuno-oncology therapies. IMAB received a $200 million upfront payment for licensing and milestone agreement and is eligible to receive up to $1.74 billion upon successful development of the drug Lemzoparlimab. And this month IMAB raised $148 million through a private placement with multiple U.S. and Asian biotech investment funds.

The company’s stock hit its record low of $9.30 in February, due to the worsening pandemic situation in China and the U.S. However, the stock has gained more than 410% since then to hit its all-time high of $47.46 on September 30. The stock has gained 224.6% to date.

View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.